Novel Systemic Drugs for Cutaneous T-Cell Lymphoma

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 1, 2011, Pages 70-93

  Lech Maranda, Ewa ^a   Robak, Ewa ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Bexarotene; Cutaneous t cell lymphoma; Denileukin diftitox; Histone deacetylase inhibitors; Mycosis fungoides; S zary syndrome

Indexed keywords

AGATOLIMOD; ALEMTUZUMAB; ALPHA INTERFERON; ALRT 1069; AROTINOID; BCX 17; BEXAROTENE; BORTEZOMIB; DENILEUKIN DIFTITOX; ETRETIN; ETRETINATE; FORODESINE; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; IMMUNOTOXIN LMB2; INTERFERON; ISOTRETINOIN; ISTODAX; MONOCLONAL ANTIBODY; PEGINTERFERON ALPHA2A; PLACEBO; PRALATREXATE; PROTEASOME INHIBITOR; RECOMBINANT INTERLEUKIN 12; RETINOID; RETINOID DERIVATIVE; REXINOID; ROMIDEPSIN; TAU INTERFERON; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VORINOSTAT; ZANOLIMUMAB;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; B CELL LYMPHOMA; BACKACHE; BIOLOGICAL ACTIVITY; BLOOD DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARDIOTOXICITY; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DEHYDRATION; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; EDEMA; FATIGUE; FLU LIKE SYNDROME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GRANULOCYTOPENIA; HAIRY CELL LEUKEMIA; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOTHYROIDISM; INFECTION; INFECTION COMPLICATION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LEUKOPENIA; LIPID METABOLISM; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; OPTIMAL DRUG DOSE; PAIN; PANCREATITIS; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; PUVA; QT PROLONGATION; RECOMMENDED DRUG DOSE; RIGOR; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; ST SEGMENT; ST SEGMENT DEPRESSION; SWEATING; SYSTEMIC THERAPY; THORAX PAIN; THROMBOCYTOPENIA; THYROID FUNCTION; UNSPECIFIED SIDE EFFECT; URINARY CAST; URTICARIA;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUGS, INVESTIGATIONAL; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAVENOUS; LYMPHOMA, T-CELL; MODELS, BIOLOGICAL; SKIN NEOPLASMS;

EID: 78650951916     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211793980051     Document Type: Article

References (231)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
2. Bagot M. Introduction: Cutaneous T-cell lymphoma (CTCL)- classification, staging, and treatment options. Dermatol Clin 2008; 26 (Suppl 1): 3-12.
3. Foss F, Whittaker S. CTCL: The most common type of primary cutaneous lymphoma: introduction. Semin Oncol 2006; 33 (Suppl 3): 1-2.
4. Whittaker S. Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL). Semin Oncol 2006; 33 (Suppl 3): 3-6.
5. Bensussan, A., Bagot, M., Boumsell, L., Moretta, A. Novel means for the diagnosis and therapy of CTCL. US20050074761 (2005).
6. Batycka-Baran A, Reich A, Jankowska-Konsur A, Maj J. New trends in the management of mycosis fungoides and Sezary syndrome. Post Dermatol Alergol 2009; 26: 41-55.
7. Stadler R, Kremer A. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): From retinoids to rexinoids. Semin Oncol 2006; 33 (Suppl 3): 7-10.
8. Petkovich M. Regulation of gene expression by vitamin A: The role of nuclear retinoic acid receptors. Annu Rev of Nutr 1992; 12: 443-71.
9. Zhang XK, Pfahl M. Hetero - and homodimeric receptors in thyroid hormone and vitamin A action. Receptor 1993; 3: 183-91.
10. Smitth M, Parkinson D, Cheson B, Friedman M. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839-64.
11. Pfahl M. Vertebrate receptors: Molecular biology, dimerization and response elements. Semin Cell Biol 1994; 5: 95-103.
12. Li JJ, Westergaard C, Ghosh P, Colburn NH. Inhibitors of both nuclear factor-kappa b and activator protein-1 activation block the neoplastic transformation response. Cancer Res 1997; 57: 3569-76.
13. Lee HY, Dawson MI, Walsh G, Nesbitt JC, Eckert R, Fuchs E, et al. Retinoic acid receptor-and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells. Cell Growth Differ 1996; 7: 997-1004.
14. Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4- hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 1999; 55: 403-10.
15. Dummer R. Emerging drugs in cutaneous T-cell lymphomas. Expert Opin Emerg Drugs 2005; 10: 381-92.
16. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: Current status and future directions. Am J Clin Dermatol 2002; 3: 193-215.
17. Dréno B, Claudy A, Meynadier J, Verret JL, Souteyrand P, Ortonne JP, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 1991; 125: 456-9.
18. Molin L, Thomsen K, Volden G, Aronsson A, Hammar H, Hellbe L, et al. Oral retinoids in mycosis fungoides and Sézary syndrome: A comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987; 67: 232-6.
19. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids J Med Chem 1994; 18: 2930-41.
20. Farol LT, Hymes KB. Bexarotene: A clinical review. Expert Rev Anticancer Ther 2004; 4: 180-8.
21. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. Clin Cancer Res 2002; 8: 1234-40.
22. Kizaki M, Dawson MI, Heyman R, Elster E, Morosetti R, Pakkala S, et al. Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro. Blood 1996, 87: 1977-84.
23. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW. A selective retinoid receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer 2006; 94: 654-60.
24. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407-10.
25. Miller VA, Benedetti FM, Rigas JR, Verret al., Pfister DG, Straus D, et al. Initial clinical trial of a selective retinoid x receptor ligand, LGD1069. J Clin Oncol 1997; 15: 790-5.
26. Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, et al. A Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 1999; 5: 1658-64.
27. Shirley MA, Wheelan P, Howell SR, Murphy RC. Oxidative metabolism of a rexinoid and rapid phase II metabolite identification by mass spectrometry. Drug Metab Dispos 1997; 10: 1144-9.
28. Howell SR, Shirley MA, Ulm EH. Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450. Correlation between retinoic acid receptor/retinoid x receptor selectivity and effects on metabolic enzymes. Drug Metab Dispos 1998; 26: 234-9.
29. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Heyman RA, Staels B, et al. Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol Cell Biol 1996; 16: 3350-60.
30. Mukherjee R, Strasser J, Jow L, Hoener P, Paterniti JR Jr, Heyman RA. RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioscler Thromb Vasc Biol 1998; 18: 272-6.
31. Nicodeme E, Nicaud M, Issandou M. Retinoids stimulate fibrinogen production both in vitro (hepatocytes) and in vivo. Induction requires activation of the retinoid X receptor. Arterioscler Thromb Vasc Biol 1995; 15: 1660-7.
32. Lu HC, Eichele G, Thaller C. Ligand-bound RXR can mediate retinoid signal transduction during embryogenesis. Development 1997; 124: 195-203.
33. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93.
34. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-71.
35. Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, et al. Comparison of selective retinoic acid receptor-and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol 2004; 51: 25-32.
36. Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014-30.
37. Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007; 157: 433-40.
38. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: A case series. J Am Acad Dermatol 2004; 51: 570-3.
39. McGinnis KS, Shapiro M, Vittorio CC, Rook AH, Junkins-Hopkins JM. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol 2003; 139: 771-5.
40. Tsirigotis P, Pappa V, Papageorgiou S, Kapsimali V, Giannopoulou V, Kaitsa I, et al. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome. Br J Dermatol 2007; 156: 1379-81.
41. Straus DJ, Duvic M, Kuzel T, Horwitz S, Demierre MF, Myskowski P, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007; 109: 1799-803.
42. Hong, B., Sarshar, S., Tse, B. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders. US20070129392 (2007).
43. Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 2006; 33(1 Suppl 3): 11-6.
44. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1987; 1: 493-8.
45. Kiyokawa T, Williams DP, Snider CE, Waters CA, Nichols JC, Strom TB, et al. Protein engineering of DAB-IL-2 fusion toxins to increase biological potency. Ann NY Acad Sci 1991; 636: 331-9.
46. Vanderspek JC, Sutherland JA, Ratnarathorn M, Howland K, Ciardelli TL, Murphy JR. DAB-389 interleukin-2 receptor binding domain mutations: Cytotoxic probes for studies of ligand-receptor interactions. J Biol Chem 1996; 271: 12145-9.
47. Bacha P, Williams DP, Waters C, Williams JM, Murphy JR, Strom TB. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med 1988; 167: 612-22.
48. Foss FM. DAB(389)IL-2 (denileukin diftitox, ONTAK): A new fusion protein technology. Clin Lymphoma 2000; 1 (1 Suppl): 27-31.
49. LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC, Schwartz G, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91: 399-405.
50. Davis, C.G., Datta, D. Modified diphtheria toxins. US20090010966 (2009).
51. Davis, C.G., Datta, D., Baker, M.P., Rust, A.J., Keen, S. Modified toxins. US20090041797 (2009).
52. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-88.
53. Carretero-Margolis CD, Fivenson DP. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides. J Am Acad Dermatol 2003; 48: 275-6.
54. Kazin R, Bujanauskas P, Vonderheid EC. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox. J Am Acad Dermatol 2008; 58 (2 Suppl): 31-2.
55. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-Cell lymphoma. J Clin Oncol 2010;
56. Negro-Vilar A, Prince HM, Duvic M, Richardson S, Sun Y, Acosta M. Efficacy and safety of denileukin diftitox (Dd) in cutaneous T- cell lymphoma (CTCL) patients: Integrated analysis of three large phase III trials. American Society of Clinical Oncology- 44th Annual Meeting. Chicago, USA (2008).
57. Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 2002; 100: 1399-403.
58. Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005; 106: 454-7.
59. Kreitman RJ, Pastan I. Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 2006; 7: 1301-11.
60. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622-36.
61. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009; 23: 1-13.
62. Bunn PA Jr, Foon KA, Ihde DC, Longo DL, Eddy J, Winkler CF, et al. Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984; 101: 484-7.
63. Johnson, H.M., Pontzer, C.H., Subramaniam, P.S., Villarete, L.H., Campos, J. Low-toxicity human interferon-alpha analogs. US6204022 (2001).
64. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, et al. Rational design of a potent, long-lasting form of interferon: A 40kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12: 195-202.
65. Masci P, Bukowski RM, Patten PA, Osborn BL, Borden EC. New and modified interferon alfas: Preclinical and clinical data. Curr Oncol Rep 2003; 5: 108-13.
66. Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, et al. Phase I trial of 40kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001; 19: 1312-9.
67. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 2001; 297: 1059-66.
68. Zeuzem S, Heathcote JE, Martin N, Nieforth K, Modi M. Peginterferon alfa-2a (40kDa) monotherapy: A novel agent for chronic hepatitis C therapy. Expert Opin Investig Drugs 2001; 10: 2201-13.
69. Hadziyannis SJ, Papatheodoridis GV. Peg-interferon-alpha2a (40kDa) for chronic hepatitis C. Expert Opin Pharmacother 2003; 4: 541-51.
70. Matthews SJ, McCoy C. Peginterferon alfa-2a: A review of approved and investigational uses. Clin Ther 2004; 26: 991-1025.
71. Mikszta, J.A., Dekker, III J.P., Pettis, R.J., Alchas, P.G. Method for delivering interferons to the intradermal compartment. US20050008683 (2005).
72. Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70: 273-86.
73. Bunn PA Jr, Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986; 57(8 Suppl): 1689-95.
74. VanderMolen LA, Steis RG, Duffey PL, Foon KA, Smith JW 2nd, Clark JW, et al. Low-versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J Natl Cancer Inst 1990; 82: 235-8.
75. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003; 16: 311-21.
76. Stadler R, Otte HG, Luger T, Henz BM, Kühl P, Zwingers T, et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-81.
77. Foss FM, Ihde DC, Linnoila IR, Fischmann AB, Schechter GP, Cotelingam JD, et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1994; 12: 2051-9.
78. McGinnis KS, Ubriani R, Newton S, Junkins-Hopkins JM, Vittorio CC, Kim EJ, et al. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome. Arch Dermatol 2005; 141: 1176-8.
79. Dummer R, Döbbeling U, Geertsen R, Willers J, Burg G, Pavlovic J. Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication. Blood 2001; 97: 523-7.
80. Dummer R, Hassel JC, Fellenberg F, Eichmüller S, Maier T, Slos P, et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004; 104: 1631-8.
81. Urosevic M. Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs 2007; 8: 493-8.
82. Godkin JD, Bazer FW, Roberts RM. Ovine trophoblast protein 1, an early secreted blastocyst protein, binds specifically to uterine endometrium and affects protein synthesis. Endocrinology 1984; 114: 120-30.
83. Imakawa K, Anthony RV, Kazemi M, Marotti KR, Polites HG, Roberts RM. Interferon like sequence of ovine trophoblast protein secreted by embryonic trophectoderm. Nature 1987; 330: 377-9.
84. Stewart HJ, McCann SH, Barker PJ, Lee KE, Lamming GE, Flint AP. Interferon sequence homology and receptor binding activity of ovine trophoblast antiluteolytic protein. J Endocrinol 1987; 115: 13-5.
85. Soos, J.M., Schiffenbauer, J., Johnson, H.M. Orally-administered interferon-tau compositions and methods. US20030012766 (2003).
86. Brunda MJ, Gately MK. Interleukin-12: Potential role in cancer therapy. Important Adv Oncol 1995: 3-18.
87. Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci 2001; 941: 177-84.
88. Rook, A.H. Methods for treatment of cutaneous T-cell lymphoma. US7052685 (2006).
89. Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 2006; 55: 807-13.
90. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in hematologic malignancies. Curr Mol Med 2009; 9: 324-35.
91. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
92. Bauer S, Kirschning CJ, Häcker H, Redecke V, Hausmann S, Akira S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001; 98: 9237-42.
93. Chuang T, Ulevitch RJ. Identification of hTLR10: A novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 2001; 1518: 157-61.
94. Dedea, D. Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins. US20040022786 (2004).
95. Tomai, M.A., Hammerbeck, D.M., Swingle, K.F. Immune response modifier compounds for treatment of TH2 mediated and related diseases. US6039969 (2000).
96. Tomai, M.A., Hammerbeck, D.M., Swingle, K.F. Immune response modifier compounds for treatment of TH2 mediated and related diseases. US6696076 (2004).
97. Gerster, J.F. Process for imidazo [4,5-C]quinolin-4-amines. US5367076 (1994).
98. Krieg, A.M., Klinman, D., Steinberg, A.D. Immunomodulatory oligonucleotides. US6194388 (2001).
99. Rook, A.H., Benoit, B.M., Wysocka, M., Bray, S.M., Miller, R.L., Tomai, M.A. Treatment for cutaneous T cell lymphoma. US20090246174 (2009).
100. [100] Kim Y, Girardi M, Duvic M, Kuzel T, Rook A, Link B, et al. TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphoma (CTCL) with CPG7909. American Society of Haematology - 46th Annual Meeting. San Diego, USA (2004), abstract 743.
101. Available from URL: http://clinicaltrials.gov/ct2/show/ NCT00091208
102. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-5.
103. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-80.
104. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998; 20: 615-26.
105. Nakayama T, Takami Y. Participation of histones and histone-modifying enzymes in cell functions through alterations in chromatin structure. J Biochem 2001; 129: 491-9.
106. Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004; 10: 2289-98.
107. Lech-Maranda E, Robak E, Korycka A, Robak T. Depsipeptide (FK228) as a novel histone deacetylase mechanism of action and anticancer activity. Mini Rev Med Chem 2007; 7: 1062-9.
108. Shigematsu N, Ueda H, Takase S, Tanaka H, Yamamoto K, Tada T. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J Antibiot (Tokyo) 1994; 47: 311-4.
109. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994; 47: 315-23.
110. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994; 47: 301-10.
111. Wang R, Brunner T, Zhang L, Shi Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene 1998; 17: 1503-8.
112. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem1994; 58: 1579-83.
113. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998; 241: 126-33.
114. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001; 48 (Suppl 1): 20-6.
115. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62: 4916-21.
116. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, et al. P21-dependent G(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000; 83: 817-25.
117. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-6.
118. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11: 77-84.
119. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63: 4460-71.
120. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004; 101: 18030-5.
121. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002; 97: 290-6.
122. Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, Matsuo M, et al. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 2003; 66: 897-906.
123. Rajski, S.R., Wassarman, D.A., Restituyo, J.A. FK228 analogs and methods of making and using the same. US 20060128660 (2006).
124. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718-28.
125. Fouladi M, Furman WL, Chin T, Freeman BB 3rd, Dudkin L, Stewart CF, et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: A Children's Oncology Group report. J Clin Oncol 2006; 24: 3678-85.
126. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959-67.
127. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98: 2865-8.
128. Whittaker S, McCulloch W, Robak T, Baran E, Prentice A. American Society of Clinical Oncology-42th Annual Meeting. Atlanta, USA (2006).
129. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-7.
130. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006; 12: 3762-73.
131. Andreef M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: A phase II clinical trial with a differentiation-inducing agent. Blood 1992; 80: 2604-9.
132. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93: 5705-8.
133. Finnin MS, Donigan JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401: 188-93.
134. Remiszewski SW, Sambucetti LC, Atadja P, Bair KW, Cornell WD, Green MA, et al. Inhibitors of human histone deacetylase: Synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem 2002; 45: 753-7.
135. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92: 1210-16.
136. Kelly WK, O'Connor OA, Marks PA. Histone deacetylase inhibitors: From target to clinical trials. Expert Opin Investig Drugs 2002; 11: 1695-713.
137. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003-7.
138. Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 2000; 6: 6: 849-66.
139. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999; 18: 7016-25.
140. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833-8.
141. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-62.
142. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003, 278: 12579-89.
143. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002; 21: 427-36.
144. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor Curtelli B, Tong W, et al. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9: 3578-88.
145. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247-52.
146. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007; 13: 2318-22.
147. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-9.
148. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-15.
149. Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T- cell lymphoma. Clin Lymphoma Myeloma 2009; 9: 412-6.
150. Richon, V.M., Frankel, S.R., Averbuch, S. Combination methods of saha and targretin for treating cancer. US20090227674 (2009).
151. Frankel, S.R., Deutsch, P.J., Randolph, S., Fine, B. Methods of using saha and bortezomib for treating cancer. US20090247549 (2009).
152. Badros, A. Z. Methods of using SAHA and bortezomib for treating multiple myeloma. US20100113392 (2010).
153. Melvin, L.S., Graupe, M., Venkataramani, C. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds. WO2010014611 (2010).
154. Lee, K. C., Sun, E. T., Wang, H. Imidazo [1,2-a]pyridine derivatives: Preparation and pharmaceutical applications. US20100105721 (2010).
155. Dickens, J. W.J., Houpis, I. N., Lang, Y. L., Leys, C., Stokbroekx, S. C. M., Weerts, J. E. E. Mono-hydrochloric salts of an inhibitor of histone deacetylase. US20100130523 (2010).
156. Ten Holte, P., Van Emelen, K., Angibaud, P. R., Marconnet-Decrane, L. F. B., Meerpoel, L. Imidazolinone and hydantoine derivatives as novel inhibitors of histone deacetylase. US20100160321 (2010).
157. Van Emelen, K., Verdonck, M. G. C., Van Brandt, S. F. A., Angibaud, P. R. J.-C., Meerpoel, L., Dyatkin, A. B. Inhibitors of histone deacetylase. EP1485099 (2010).
158. Richon, V. M., Chiao, J. H., Kelly, W. K., Miller, T. A. Methods of treating cancer. US7732490 (2010).
159. Rawandi E, O'Brien S. Alemtuzumab. Expert Rev Anticancer Ther 2005; 5: 39-51.
160. Xia MQ, Hale G, Lifely MR, Ferguson MA, Campbell D, Packman L, et al. Structure of the CAMPATH-1 antigen, a glycosyl-phosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993; 293: 633-40.
161. Hederer RA, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, et al. The CD45 tyrosine phosphatase regulates Campath-1H (CD52) - induced TCR-dependent signal transduction in human T cells. Int Immunol 2000; 12: 505-16.
162. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22: 185-91.
163. Watanabe T, Masuyama J, Sohma Y, Inazawa H, Horie K, Kojima K, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 2006; 120: 247-59.
164. Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701-2.
165. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748-52.
166. Moreau T, Coles A, Wing M, Thorpe J, Miller D, Moseley I,et al. CAMPATH-IH in multiple sclerosis. Mult Scler 1996; 1: 357-65.
167. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 2: 1620-22.
168. Hale G, Waldmann H. CAMPATH-1 monoclonal antibodies in bone marrow transplantation. J Hematother 1994, 3: 15-31.
169. Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999; 26 (Suppl 14): 52-7.
170. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007; 26: 3644-53.
171. Robak T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2008; 8: 1033-51.
172. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-23.
173. Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: Alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 2008; 13: 167-74.
174. Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Langer W, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002; 20: 205-13.
175. Rosenblum MD, LaBelle JL, Chang CC, Margolis DA, Schauer DW, Vesole DH. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood 2004; 103: 1969-71.
176. Riechmann LM, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-7.
177. Page MJ, Sydenham MA. A structure of the therapeutic antibody CAMPATH-1H lab in complex with a synthetic peptide antigen. J Mol Biol 1999; 289: 293-301.
178. Page MJ, Sydenham MA. High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells. Biotechnology 1991; 9: 64-8.
179. Sheeley DM, Merrill BM, Taylor LC. Characterization of monoclonal antibody glycosylation: Comparison of terminal alpha-linked galactose. Anal Biochem 1997; 247: 102-10.
180. Xia MQ, Hale G, Waldmann H. Efficient complement mediated lysis of cells contaning the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993; 30: 1089-96.
181. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-6.
182. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2002; 3: 137-43.
183. Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclasic, caspase-independent apoptotic pathway in B- lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004; 83: 634-45.
184. Zent CS, Chen JB, Kurten RC, Kaushal GP, Lacy HM, Schichman SA. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004; 28: 495-507.
185. Smolewski P, Szmigielska-Kaplon A, Cebula B, Jamroziak K, Rogalinska M, Kilianska Z, et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma 2005; 46: 87-100.
186. Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006; 20: 272-9.
187. Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948-55.
188. Tang SC, Hewitt K, Reis MD, Berinstein NL. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma 1996; 24: 93-101.
189. Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: Assay development and validation. J Immunol Methods 2002; 260: 285-302.
190. Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007; 64: 278-91.
191. Montillo M, Cafro AM, Tedeschi A, Brando B, Oreste P, Veronese S, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002; 87: 695-700.
192. Robak T. Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs 2005; 19: 9-22.
193. Keating M, Coutré S, Rai K, Osterborg A, Faderl S, Kennedy B, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004; 4: 220-7.
194. Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004; 18: 484-90.
195. Thursky KA, Worth LJ, Seymour JF, Prince H, Slavin MA. Spectrum of infection risk and recomendations for prophylaxis and screening among patients lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006; 132: 3-12.
196. Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, et al. Phase II study of alemtuzumab in chroniclymphoproli-ferative disorders. Cancer 2003; 98:773-8.
197. Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 2004; 104: 655-8.
198. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. European Study Group of CAMPATH- 1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998; 16: 3257-63.
199. Kennedy GA, Seymour JF, Wolf M, Januszewicz H, Davison J, McCormack C, et al. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol 2003; 71: 250-6.
200. Bernengo MG, Quaglino P, Comessatti A, Ortoncelli M, Novelli M, Lisa F, et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: Clinical and immunologic findings in 14 patients. Haematologica 2007; 92: 784-94.
201. Alinari L, Geskin L, Grady T, Baiocchi RA, Bechtel MA, Porcu P. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly. Leuk Res 2008; 32: 1299-303.
202. Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: A single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 2009; 50: 1969-76.
203. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, et al. High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996; 14: 845-51.
204. Fishwild DM, Hudson DV, Deshpande U, Kung AH. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates. Clin Immunol 1999; 92: 138-52.
205. Villadsen LS, Havenith CEG, Skov L, Dam TN, Dagncs-Hansen F, Rygaard J, et al. Depletion of human CD4+ T cells in peripheral blood and skin by HuMax-CD4. J Investig Dermatol 2004; 123: 2 (A56).
206. Obitz E, Kim YH, Iversen L, Osterborg A, Jensen P, Baadsgaard O, et al. HuMax-CD4, a fully human monoclonal antibody: Early results of an ongoing phase II trial in Cutaneous T Cell Lymphoma (CTCL). Blood 2003; 102: 11 (Abs 2383).
207. Kim YH, Obitz E, Iversen L, Oesterborg A, Whittaker S, Illidge TM, et al. HuMax-CD4, fully human monoclonal antibody: Phase II trial in cutaneous T cell lymphoma. J Investig Dermatol 2004; 122: 3 (A57).
208. Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, et al. Clinical efficacy of zanolimumab (HuMax-CD4): Two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109: 4655-62.
209. Available from URL: http://clinicaltrials.gov/ct2/show/ NCT00127881
210. Evans GB, Furneaux RH, Lewandowicz A, Schramm VL, Tyler PC. Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. J Med Chem 2003; 46: 5271-6.
211. Clinch K, Evans GB, Fleet GW, Furneaux RH, Johnson SW, Lenz DH, et al. Synthesis and bio-activities of L-enantiomers of two potent transition state analogue inhibitor of purine nucleoside phosphorylases. Org Biomol Chem 2006; 4: 1131-9.
212. Robak T, Korycka A, Lech-Maranda E, Robak P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 2009; 14: 1183-226.
213. Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2006; 108: 2392-8.
214. Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 2009; 21: 131-7.
215. Korycka A, Lech-Mara da E, Robak T. Novel purine nucleoside analogues for hematological malignancies. Recent Pat Anticancer Drug Discov 2008; 3:123-36.
216. Gupta, P.K., Munk, S.A. Process for the preparation of 9-beta-anomeric nucleoside analogs. CA2493724 (2008).
217. Evans, G.B., Hubert, R., Lrnz, D.H., Schramm, V.L., Tyler, P.C, Zubkova, O.V. Inhibitors of nucleoside phosphorylases and nucleosidases. US20060160765 (2006).
218. Schramm, V.L. Transition state structure and inhibitors of thymidine phosphorylases. US20070275988 (2007).
219. Duvic M, Forero-Torres A, Foss F, Olsen E, Pinter-Brown L, Kim Y. Long-term treatment of CTCL wih the oral PNP inhibitor, forodesine. American Society of Oncology - 45th Annual Meeting, Orlando USA (2009).
220. Available from URL: http://clinicaltrials.gov/ct2/show/ NCT00501735
221. Horwitz SM. Novel therapies for cutaneous T-cell lymphomas. Clin Lymphoma Myeloma 2008;8 (Suppl 5):S187-92.
222. Zain JM, O'Connor O. Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol 2010; 92: 33-44.
223. Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10-propargyl 10- deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003; 44:1027-35.
224. O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ, et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007; 139: 425-8.
225. O'Connor OA, Hamlin PA, Gerecitano J, Portlock CS, Noy A, Moskowitz C, et al. Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience. American Society of Haematology - 48th Annual Meeting, Orlando, USA (2006).
226. Horwitz SM, Duvc M, Kim Y, et al. Low-dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: preliminary results of a multi-center dose finding trial. 10th International Conference on Malignant Lymphoma, Lugano, Switzerland (2008).
227. D'Alessandro A, Pieroni L, Ronci M, D'Aguanno S, Federici G, Urbani A. Proteasome inhibitors therapeutic strategies for cancer. Recent Pat Anticancer Drug Discov 2009; 4: 73-82.
228. Mitchell BS. The proteasome-an emerging therapeutic target in cancer. N Engl J Med 2003; 348: 2597-8.
229. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004; 22: 304-11.
230. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28: 2259-66.
231. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 4293-7.